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ABSTRACT

The purpose of this study is to develop a unique nanoparticulated system that has the
capability of providing sustained drug delivery into the eyes. In ophthalmic preparations, poor
ocular drug delivery of ocular dosage form is due to the production of tears and impermeability
through corneal epithelium. The usage of liposomes in ophthalmic disorders shows promising
results in ocular drug delivery. Liposomes are bilayered, microscopic vesicles surrounded by the
aqueous compartments. Liposomes have the ability to encapsulate both hydrophilic and
hydrophobic drugs. This unique property of liposomes helps in delivering the drug at specific
site. This invention involves three major components: first, encapsulating of both hydrophilic
and hydrophobic drugs into the liposomes. Second, incorporate liposomes into polymeric coating
material with a volatile carrier solvent. Finally, apply liposome incorporated coating composite
into intraocular lenses. When volatile solvent evaporates, the coated polymer with liposomes will
form a thin film upon the intraocular lens. Local application of encapsulated coated intraocular
lenses helps in the successful controlled, sustained time release of the drug in to the target site
helps in prevention and treatment of ophthalmic diseases.
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INTRODUCTION
The eye is a unique and precious organ in human body, characterized by its complex
structure and impermeable to foreign substances including drugs. The drug delivery to the
specified targeted region of eye is difficult because of the specialized anatomical and
physiological nature of the eye. The physiological and anatomical barriers allow only a small
fraction of the drug, usually 1-5% of the instilled dose to be effectively absorbed. The two major
constraints that result in relatively poor ocular bioavailability are the pre corneal loss factions
and the relative impermeability of the corneal epithelium membrane. [1]
The structure of eye can be explained under two segments i.e. anterior segment and
posterior segment. Anterior segment consists of front part of the eye which includes pupil,
cornea, iris, ciliary body, aqueous humor and lens where as posterior segment includes two third
of eye, includes vitreous humor, retina, choroid, macula and optic nerves. [18]
Fig1: The Anatomy of the Eye [15]
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Millions of people suffer from a wide variety of ocular diseases, many of which lead to
visual impairment and ocular blindness. Certain ocular diseases like Cataracts, Age related
Macula and Glaucoma are very common in aging people.
Macular degeneration is the leading cause of severe vision loss in many people over age
60. As the disease develops with person ages, it is often referred to as age-related macular
degeneration (AMD). Age-related Macular Degeneration is a chronic, degenerative disease of
the macula, the central portion of the retina that results primarily in central vision loss whereas
the peripheral vision remains unaffected. It occurs when the small central portion of the retina,
known as the macula, deteriorates. It is the third major cause of adult blindness worldwide, and
the first in industrialized countries [2].
Fig2: Macular Degeneration [15]

There are two main types of age-related macular degeneration:
Dry AMD:
The "dry" form of macular degeneration is characterized by the presence of yellow
deposits, called “drusen” in the macula. As the drusen grow in size and increase in number, they
may lead to a dimming of vision. In more advanced stages of dry macular degeneration, there is
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also a thinning of the light-sensitive layer of cells in the macula leading to atrophy, or tissue
death. In the atrophic form of dry macular degeneration, patients may have blind spots in the
center of their vision. [8]
Wet AMD:
The "wet" form of macular degeneration is characterized by the growth of abnormal
blood vessels from the choroid underneath the macula. It is called choroidal neovascularization.
These blood vessels leak blood and fluid into the retina, causing distortion of vision that makes
straight lines look wavy, as well as blind spots and loss of central vision. These abnormal blood
vessels eventually scar, leading to permanent loss of central vision. [8]
Wet macular degeneration further falls into two categories:
 Occult: Vision loss is not as severe as compared to the classic form because of
comparatively less new blood vessel growth beneath the retina and the consequent
leakage.
 Classic: Usually produces more severe vision loss where new blood vessel growth and
scarring beneath the retina is more severe. [2]
Other major causes of blindness in older individuals include: Presbyopia, Cataract,
Glaucoma and Diabetic Retinopathy.
Presbyopia is a condition where there is a difficulty to see the objects close by, because
the eye lens loses its ability to focus. These age-related changes occur within the proteins in the
lens, making the lens harder and less elastic over time.
Fig3: Presbyopia of the Eye [15]
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Glaucoma is an eye condition that develops when too much fluid pressure builds up
inside the eye. The increased pressure, called intraocular pressure, can damage the optic nerve,
which transmits packets of images to the brain. If damage to the optic nerve from high eye
pressure continues, glaucoma will cause loss of vision. Without treatment, glaucoma can cause
total permanent blindness within a few years.
Fig4: Glaucoma [15]

Diabetic Retinopathy is caused by damage to the fragile blood vessels of the retina. In
Diabetic Retinopathy blood vessels may swell and leaks fluids. It could further develop cataracts
and glaucoma. It results in changes in veins, arteries and capillaries in the body.
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Fig5: Diabetic Retinopathy [15]

Cataracts are changes in clarity of the natural lens inside the eye by the accumulation of
turbulent fluid, which gradually degrade visual quality. Cataract surgery is very successful
treatment for the restoration of vision. During surgery, the clouded lens i.e. turbulent fluid is
removed and replaced it with a clear, intra ocular lens. In Cataract Surgery, by using an operating
microscope, a small incision, usually around 3 millimeters long, is made in the eye. Precise
surgical instruments are used to break apart and remove the cloudy lens from the eye. In most
cases, the natural lens is then replaced with a permanent intraocular lens (IOL) implant. This IOL
is clear and is intended to stay in the eye forever. The incision typically does not require stitches.
This small incision, no-stitch technique, has drastically reduced the recovery time for modern
cataract surgery. [6], [7]
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Fig6: Cataracts [15]

Fig 7: Cataract Surgery [15]
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Cataract surgery can increase the risk of retinal detachment slightly. Other complications
after the surgery include infection, bleeding, inflammation, loss of vision, double vision, and
high or low eye pressure. Intraocular drug delivery is the best mode to achieve highest
intraocular bioavailability in the posterior segment tissues such as the macula or fovea. This is
possible because it is the only drug delivery which directly circumvents the Blood Retinal
Barrier (BRB) and thus highest peak Intravitreal or intraretinal drug concentrations are attained.
So far, the main treatment strategy for the diseases of the posterior segment mainly, the Age
Related Macular Degeneration is the intravitreal injection, which involves direct injection of the
drugs into the vitreous humor. The advantages of this treatment option are that it directly
broaches BRB and high drug levels in the retina are achieved. But the main problem is that good
patient compliance isn’t achieved as this is a very painful technique. Besides, there are several
other complications such as increased intraocular pressure, floaters, vitreous hemorrhage,
transient blurry vision, retinal tears, retinal detachment, development of endophthalmitis,
glaucoma and cataract. Endophthalmitis is the inflammatory condition of the intraocular cavities
i.e. the aqueous and vitreous humor usually caused by infection. [1]
Fig 8: Intravitreal Injection [15]
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Thus there is a need to develop a simple, non-invasive technique which besides
improving the ocular bioavailability and therapeutic efficacy achieves better patient compliance
and overcomes the problems encountered with the previous techniques.
Intra Ocular Lens (IOL):
In the past, people had to use very thick eye glasses or special contact lenses to be able to
see after cataract surgery. Now, several types of IOL implant are available to help people to
improve their vision. IOL is the artificial lens implanted during the Cataract surgery, to replace
the natural lens of eye, as it becomes cloudy. Basically natural lens of eye is made up of proteins,
the linkage formed between the proteins leads to the formation of the cloudy, turbulent fluid in
the eye and this causes the blurred vision of the eye. Intraocular lens works as natural lens of eye.
They basically provide a clear, optical path and also restorative refractive capability to the eye [3].
IOLs are made of either hard plastic or soft, foldable polymers such as PMMA,
hydrophilic acrylics, poly (2-hydroxyethyl methacrylate) or silicone. In 1981 for the First time
FDA approved IOL. [9] The basic function of IOL is to focus the light onto the retina, where the
packets of images are converted into electrical impulses that travel to the brain. The basic
construction of IOL is shown at the following figure.
Fig 9: Intraocular Lens [17]

The round, corrective central portion acts as the refractive element with two arms which
provide structural support for the lens in the lens capsule of the eye [4]. The center viewing zone
is called the optic. This is a clear, round disc measuring 5.5 to 6.5 mm in diameter. On opposite
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side of the optic, there are two flexible struts are present, which are called as Haptics. These
Haptics acts like tension loaded springs to automatically center the lens within the compartment.
There are different types of IOL’s are used in cataract surgery. Mainly three types of
IOL’s are used in cataract surgery. They are
 Monofocal lens
 Multifocal lens
 Toric lens
Monofocal lenses are used for distance vision, by provides a single focal point.
Multifocal IOL’s are advanced type of IOL’s used for multiple focal points and reduces the
usage of eyeglasses or contact lenses after the cataract surgery. Toric lenses are the special type
of lenses used to reduce the astigmatism of the eye at time of surgery.

[9], [10]

Examples include:

Crystalens, AcrySof IQReSTOR from Alcon’s and Technis and ReZoom from Abott Medical
Optics.
IOLs are commercially available as:
 Premium IOLs,
 Toric IOLs,
 Blue light-filtering IOLs,
 Aspheric IOLs,
 Piggyback IOLs.
Fig 10: Types of Intraocular lens [17]

The main advantage of using IOLs is that they allow us to study sustained release of
therapeutic levels of drug for a desired period of time, thus overcoming Blood Retinal Barrier
which is associated with systemic drug delivery. [4], [10]
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Nanoparticles:
Nanoparticles are submicron sized colloidal particles with lengths in 2 or 3 dimensions
greater than 1nm and smaller than 100nm. This sub-class of ultra-fine particles may or may not
exhibit a size-related intensive property. The small size of the nanoparticles allows them to
efficiently penetrate across the biological barriers through small capillaries all over the body.
This allows nanoparticles, to access into various cells and cellular compartments including the
nucleus, thus allowing efficient drug accumulation at the actual targeted site. The unwanted side
effects and the toxicity of the drug are thus reduced while enhancing the therapeutic efficiency[5].
There are several other advantages of using nanoparticles as drug delivery systems:
 Solubility of the drug is increased, can be used for all routes of administration.
 Protects the drug from degradation i.e. protect the drug from chemical or
enzymatic hydrolysis
 Can be formulated easily and rapidly.
 Sustained drug release and prolonged therapeutic activity
 Novel drug delivery tool for chronic ocular diseases
 Site-specific targeting -surface modification with ligands
 P-glycoprotein circumvention –higher cellular permeability
 Efficient in crossing membrane barriers -blood retinal barrier
 Act as an inert carrier for ophthalmic drugs
 More stable than colloidal system
 Time release studies
In ocular drug delivery, an important consideration would be to obtain therapeutic
concentrations within the retina by increasing the relative permeability of the Blood Retinal
Barrier(BRB). Use of nanoparticles is an effective strategy to enhance the BRB transport. There
are various methods for loading the drugs onto nanoparticles such as encapsulation, surface
attachment or entrapment.
In this research, encapsulation is the method followed for loading the drug. As
nanoparticles are colloidal systems, the stability of these formulations is very important. This can
be improved by the use of polymeric surfactants, or other modifiers. The surfactants are adsorbed
or grafted to the particles and form a layer, which produces repulsive force between the
nanoparticles and prevent flocculation [5].
Nanoparticulated Ocular Drug Delivery
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It has been shown that the drug delivery using nanoparticles can enhance the
bioavailability of drug in target site. In the current research we develop a unique nanoparticle
system i.e. liposomes as an ocular drug delivery. Liposomes are microscopic vesicles composed
of lipid bilayered membrane surrounded by aqueous compartments. The lipid bilayered
membrane mostly composed of phospholipids. These phospholipids are amphiphlic, having
hydrophilic head and hydrophobic/lipophilic tail. In the bilayered membrane these nonpolar tails
located in interior of the membrane and polar heads are pointing towards the outside of
membrane. This property helps in encapsulation of both hydrophilic and lipophilic drugs in
liposomes.

[11]

These liposomes are classified into various types based on their size i.e.

unilamellar vesicles (ULV) and multilamellar vesicles (MLV). These unilamellar vesicles again
divided into small unilamellar vesicles (SUV) and large unilamellar vesicles (LUV). These large
size vesicles can be modified into small vesicles by using sonicator. [12]
Fig 11: Nanoparticle Structure [16]
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In the current study we used time release technology which is Sustained Release (SR)
Technology. The advantages of this time-release technology are uniform release of drug
substance over time, reduction in the frequency of drug administration, reduced side effects, and
better patient compliance. Sustained release is the slow release of the drug over a time period. In
this, the drug concentration will vary with time interval because the initial release of the drug is
sufficient to provide a therapeutic dose soon after the administration and then gradual release of
the drug takes place over an extended time period.

EXPERIMENTAL METHODS
Fluorescein Sodium Salt from Sigma Chemical Company is used as a biomarker. It is a
hydrophilic fluorophore with anhydrous molecular weight of 376.3gm and has an absorption
maximum at 494nm and emission maximum at 521nm. It is an orange-red powdered compound
that exhibits intense greenish-yellow fluorescence. Major applications of Fluorescein include
Nanolithography, nanoparticles, and thin films. It is used in various areas of ophthalmology,
especially in retinal vasculature imaging (diagnosis of Diabetic Retinopathy) to reveal corneal
lesions and as a systemic biomarker in numerous pharmacokinetic studies. The Flurometer used
is Ocean Optics 2000+.from Ocean Optics. The Sonicator used in this study is UP100H from
Hielscher ultrasound technology.
Nanoemulsions are dispersions of fine droplets (in nanometer range) in a dispersion
medium. So they are thermodynamically unstable. Thus they require considerable mechanical
energy during their preparation to enhance the stability. Choosing the oil phase and the
surfactants are important consideration in the formulation of nanoemulsions, so as to be able to
carry both polar and non-polar drugs and improve control over the release of therapeutic
molecules. Most widely used oils are various fixed oils of vegetable origin. Oils used: Castor oil,
a hydrophilic non-ionic surfactant is the oil used. Other vegetable oils such as olive oil, canola
oil and almond oil are also used.
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Surfactants:
Surfynol-465 has a great solubility in water. All the Surfynol 400 Series surfactants have
a unique combination of formulating benefits like greater dispersion, emulsification, wetting etc.
Polaxomer 407 is a hydrophilic, non-ionic copolymer, mostly used in cosmetics. This
surfactant also used in contact lens cleaning solution. It is non toxic so it is widely used in oral
and topical pharmaceutical products.
PEG 3350 is an excipient used as an emulsifier, binder and surfactant. It improves
resistance to moisture and oxidation. Polyethylene is a polymerized ethylene resin and glycol is a
hydric alcohol. It is highly soluble in water, so it can couple to hydrophobic molecules.
Asolectin is a mixture of phospholipids. It is made from soybean and mainly used as oil
in water emulsifier. It is used to reconstitute acetylcholine receptor into liposomes. Asolectin
comprises roughly equal proportions of lecithin, cephalin and phosphatidylinositol along with
minor amounts of other phospholipids and polar lipids.

Drugs Used:
Two pharmacological classes of drugs have been used:
Antibiotics – Vancomycin
It is a glycopeptides antibiotic. Anti-bacterial mostly used to treat colitis.
Anti-inflammatory – Alclofenac
It is a Non-steroidal Anti-inflammatory drug, analgesic and anti-pyretic.

Coating:
Coating is an important part of the sustained release forms.
Purpose of coating;
 Obtain functional coats.
 Provide chemical stability.
 Enhance patient acceptance

Properties of the coating material for IOL coating:
 Biodegradable,
 Highly flexible polymeric coating with sustained release effect,
Nanoparticulated Ocular Drug Delivery
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 Easy applicability,
 Fast drying or curing,
 Excellent adhesion to IOL,
 Low solvent emission and should be safe in workplace,
 Should leave no residue after removal from the applied surface.

Materials used for the preparation of the coating formulation:
Polycaprolactone is the polymer used. It is a biodegradable, synthetic thermoplastic
polymer used in a number of biomedical applications. It is hydrophobic and slow-degrading. It is
most commonly used in controlled drug delivery systems and in implants. [14]
Collodion Solution from Fluke Analytical, Contains: Nitrocellulose, Ethyl alcohol and
Ether Solution. It is an excellent coating material and when the solvent is evaporated it leaves a
tough, clear, transparent film. [14]
Hydroxy Propyl Methyl Cellulose is a biodegradable, base celluloid compound that is
highly water soluble. It is also called s hypromellose. Hypromellose 2% solution has been
documented to be used during surgery to aid in corneal protection and during orbital surgery. It
is a good coating material that forms a clear transparent film on IOL. It is available in different
molecular weights. In this experiment we used three different molecular weights i.e. 10000,
90000 and 120000.

Materials for the preparation of PMMA implants:
PMMA:
Poly (methyl methacrylate) is a synthetic, transparent plastic, versatile biocompatible
polymeric material for coating used in a number of medical applications. It has a high surface
area and low density, which make it an excellent seeding and coating material for antibiotic
encapsulated nanoparticles. [14]
MMA:
Methyl methacrylate is a synthetic chemical used in coating formulations. Advantages of
biodegradable implants are they don’t have to be removed or absorbed or eliminated from the
body. [14]
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IOL:
Intra ocular lenses supplied by AMO-Inc, Abbott Laboratories.USA

EXPERIMENTAL PROCEDURE
For the preparation of nanoparticles, we need to prepare the stock solution of Fluorescein,
and then we need to prepare the micelles followed by the preparation of liposomes.
1M Fluorescein Stock Solution:
37.63 gm of Fluorescein Sodium Salt was taken and dissolved in a small amount of
distilled water on a hot plate with continuous stirring. Then make up the volume to 100mL.
Poloxamer 407 Solution:
1gm of Poloxamer 407 + 30ml water under low heat with constant stirring
PEG 3350 Solution:
1gm of PEG 3350 + 30ml water under low heat with constant stirring.
Preparation of PMMA implant:
Formulation 1-A:
18 g of Polymethylmethacrylate (PMMA) + 12 mL methyl methacrylate (MMA)
Formulation 1-B:
18 g of PMMA + 12 mL MMA + 5 mL EMA
Thoroughly mix the above formulation separately in a glass beaker in a chemical hood
with constant stirring. The mixture is then cast in a molding plate, made of Al or Sn with the
desired thickness. The casting plate is then kept in the oven for over 2 hours at 800C in order for
the PMMA to cure. [14]

Inverted micelle (W/O Nanoemulsion):
Formulation 2–A:
 10mL of castor oil is taken and heated gently on a low heat.
 2mL of Surfynol-465 is added to the above oil and dissolved on a low heat with constant
stirring with a magnetic bead, until it forms a homogeneous mixture.
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 Aqueous phase i.e. fluorescein is added drop wise to the above mixture, maintaining low
heat and continuous stirring until a viscous, homogeneous water-in-oil emulsion is
obtained. Approximately 30 drops i.e. 1.5 ml could be incorporated into the mixture.
 The emulsion is then kept for overnight stirring to obtain a clearer, homogeneous
emulsion.
Formulation 2-B:
 10mL of castor oil is taken and heated gently on a low heat.
 0.1 gm of Asolectin is added to the above oil and dissolved on a low heat with constant
stirring until it forms a homogeneous mixture.
 Aqueous phase i.e. fluorescein with 2ml of poloxamer 407 is added drop wise to the
above mixture, maintaining low heat and continuous stirring until a viscous,
homogeneous emulsion is obtained. Approximately 12 drops added to the mixture.
 The emulsion is then kept for overnight stirring to obtain a clearer, homogeneous
emulsion.

Liposomes (O/W/O Nanoemulsions):
Formulation 3-A:
 10 ml of Poloxamer solution is taken and heated gently under low heat.
 To the above solution inverted micelle i.e. W/O emulsion is added drop wise with
continuous stirring under low heat until it forms a homogeneous and clear solution.
 Approximately 18 drops of inverted micelle incorporated in the above solution.
Formulation 3-B:
 10 ml of PEG 3350 solution is taken and heated gently under low heat.
 To the above solution inverted micelle i.e. W/O emulsion is added drop wise with
continuous stirring under low heat until it forms a homogeneous and clear solution.
 Approximately 14 drops of inverted micelle incorporated in the above solution.
 Sonicate for 15 min.
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Coating of Nanoemulsions:
 These prepared nanoemulsions are incorporated into a polymeric coating material to
study sustained release properties.
 The coating solvent should be non-toxic and it should be easily evaporated once it is
coated on to the IOL surface.
 The coating material must be easily dried, so the coating material must prepare just
before 10 min, before the coating is done.
 Nano particles were mixed with carrying solvent and a binding agent to prepare slurry
which has good binding capacity.
Coating Formulation:
 Dissolve 0.2 g of Polycaprolactone in 2.0 mL of nitrocellulose and 2.0 mL of acetone
with constant stirring under very low heat.
 Add acetone drop by drop in the beaker until the polymer is totally dissolved.
 About 1mL of MMA is added to this to improve the adhesive nature of the coating
formulation.
 To the above formulation, Liposome (w/o/w Nanoemulsion) is added drop wise with the
continuous addition of acetone.
 Approximately 38 drops of liposome i.e. w/o/w emulsion is incorporated in coating
formulation.

Coating of PMMA implant:
Approximately 2 mL of the coating formulation is taken and coated on the PMMA
implant carefully with a paint brush.

The coated PMMA implant is then allowed to dry

overnight.

Coating of IOL:
 Intra Ocular Lens is gently held with tweezers by holding one of the Haptics.
 It is then dipped in the coated formulation gently to coat both the sides of the IOL.
 IOL is then allowed to air-dry for 24 hours by covering it with an aluminium foil.
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**Throughout the experimental procedure, all the glassware and the test tubes are covered with
aluminium foil to prevent any photo activity of Fluorescein.

Testing of IOL for Sustained Release Studies:
 Simulated vitreous humor and aqueous humor are prepared for testing the sustained
release of the drug from the coated IOL.
 The coated IOLs are then placed in them. Samples are collected from the simulated
vitreous humor on a daily basis (at 24 hour interval) and hourly basis and the
fluorescence intensity is measured.

RESULTS AND DISCUSSIONS
Evidence for Encapsulation of Liposomes:
An evidence for encapsulation of drug in to nanoparticles is provided by the Fluorescence
technique by which we can examine the nanoparticles.

Fig 12: Evidence of Nanoparticle Formulation
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The graph provides a good evidence for the encapsulation of the drug into the nanoparticles.
Fluorescein dye in aqueous solution used as a bio-marker which gives an intensive peak ( blue)
and some concentration of fluorescein dye solution trapped inside the formulation 3-A and 3-B
liposomes ( red). Graph shows a decreased intensity of fluorescence of drug in water when
compared to that of the drug in the liposomes which indicates that drug is encapsulated in to the
liposomes. This is because of the multi lamellar structure of the liposomes. The shift in the graph
which is blue shift shows an increase in the polarity of the drug and also represents the drug
movement to more hydrophilic environment.

Sustained Release Studies:
Simulated vitreous humor and aqueous humor was prepared to examine the sustained
release kinetics. A luminescence bio-marker was encapsulated inside the liposomes instead of
the antibiotic drugs in order to monitor the sustained release. We used vancomycin to simulate
the hydrophobic drug and fluorescence dye i.e. fluorescein to simulate the hydrophilic drug. The
coated Intra ocular lens with encapsulated luminescence bio marker was submerged inside the
vitreous humor or aqueous humor and the fluorescence was measured in a time interval of 1 hour
for a period of 16hours. The intensity of fluorescence indicates the amount of drug that is
released from the coating polymer into the vitreous humor and aqueous humor. Sustained release
of fluorescein dye was observed up to 16 days. The liposome thus provides the initial release of
drug.
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Table 1: Fluorescence intensities taken on an hourly basis

S.No

Time(Min)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
960

Relative
Fluorescence
Intensity
748.00
935.00
877.00
954.01
1031.00
1040.29
1123.44
1245.40
1293.00
1388.01
1483.01
1620.90
1823.21
1848.68
1869.68
1989.40

Fluroscence Intensity

Fig 13: Hourly Drug Release
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Table 1 shows the Fluorescence intensity studies taken on hourly basis i.e. for every
1hour. We took the fluorescence intensity of the drug measured for a time period of 16 hours. A
Graph was plotted on the hourly basis of drug release. This shows the increase in intensity of
fluorescence from first hour to sixteenth hour. The Fluorescence intensity increased from 748.00
(1st hour) to 1989.40 (16th hour).

Table 2: Fluorescence intensities taken on daily basis

S.No

Time( Hr)

Relative
Fluorescence Intensity

1

24

8107.21

2

48

16550.82

3

72

20032.86

4

96

26157.76

5

120

44001.84

6

144

63652.72

7

168

66919.12

8

192

70573.76

9

216

80996.00

10

240

83583.28

11

264

129129.92

12

288

125849.44

13

312

141469.12

14

336

144108.16

15

360

176436.48

16

384

196057.60
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Fig 13: Daily Drug Release
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Table 2 shows the Fluorescence intensity studies taken every 24th hour for a period of 16
days. The plotted graph for table 2 shows the drug release profile. The Fluorescence intensity
increased from 8107.21 on day 1 to 196057.60 day 16.
Increase in fluorescence intensities supports the prolonged release of the drug at a
predetermined rate by maintaining a constant drug level at a specified period of time. The
sustained release studies observed up to 16 days which shows more bioavailability of drug for
long time. Combination of different liposomes and inverted micelle can give a much prolonged
drug release which has to be further investigated.

Nanoparticulated Ocular Drug Delivery

Page 25

CONCLUSION
“Nanoparticulate drug delivery system for vitreous humor” has the ability to provide
the drug delivery into the eye. Preparation of antibiotics in a nanoparticulate form can be used to
prevent infections in treatment of cataract surgery and age related macula. Nanoparticulated drug
delivery shows lesser side effects when compared to antibiotics prepared for oral administration
and for instillation into the eye. The antibiotic drug prepared in nanoparticulate form can be
directly applied to the location of surgery which reduces the first pass metabolism. Intra ocular
lens implantation is the main feature of cataract surgery. Fluorescence studies show that the drug
is completely encapsulated into the prepared liposome nanoparticles. Sustained release study
results indicated that the prepared nanoparticles provided sustained release of the drug for about
16 days. Cytotoxicity test are to be performed in order to test the toxicity of the formulation.
Further research should be carried out by preparing different types of formulations of
nanoparticles by using different types of drugs.
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